DK2800574T3 - Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt - Google Patents
Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt Download PDFInfo
- Publication number
- DK2800574T3 DK2800574T3 DK12756729.5T DK12756729T DK2800574T3 DK 2800574 T3 DK2800574 T3 DK 2800574T3 DK 12756729 T DK12756729 T DK 12756729T DK 2800574 T3 DK2800574 T3 DK 2800574T3
- Authority
- DK
- Denmark
- Prior art keywords
- weight
- extract
- composition according
- composition
- propolis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (17)
1. Antiinflammatorisk sammensætning, omfattende a. et planteekstrakt med mindst 5 vægt%, fortrinsvis fra 5 til 20 vægt%, fordelagtigt fra 5 til 15 vægt% malvidin-3-0-p-glucosid; og b. et ekstrakt af Propolis med coffeinsyre eller en ester deraf, ferulasyre, galangin og pinocembrin; i et vægtforhold a/b planteekstrakt/P ropol is-ekstrakt, som går fra 1/4 til 4/1.
2. Sammensætning ifølge krav 1, som er i fast form eller flydende form, eller hvor planteekstrakten er et vindrueskalekstrakt, som opnås eller kan opnås med en fremgangsmåde, der omfatter koncentration af de polyphenoliske fraktioner af mindst én rød vindruekvas.
3. Sammensætning ifølge de foregående krav, omfattende - fra 0,1 til 50 vægt%, fortrinsvis fra 1 til 40 vægt%, planteekstrakt, eller - fra 20 til 80 vægt%, fortrinsvis fra 30 til 70 vægt%, Propolis-ekstrakt, eller - fra 0,1 til 50 vægt%, fortrinsvis fra 1 til 40 vægt%, planteekstrakt og fra 20 til 80 vægt%, fortrinsvis fra 30 til 70 vægt% Propolis-ekstrakt.
4. Sammensætning ifølge de foregående krav, hvor Propolis-ekstraktet omfatter • fra 0,001 til 0,2 vægt%, fortrinsvis fra 0,005 til 0,15 vægt% coffeinsyre eller en ester deraf; • fra 0,0001 til 0,005 vægt%, fortrinsvis fra 0,0005 til 0,003 vægt% ferulasyre; • fra mellem 0,05 til 10 vægt%, fortrinsvis fra 0,1 til 6 vægt% galangin; • fra 0,1 til 5 vægt%, fortrinsvis fra 0,2 til 3 vægt% pinocembrin;
5. Sammensætning ifølge de foregående krav, ligeledes omfattende capsaicin eller et antiinflammatorisk middel eller en blanding deraf.
6. Sammensætning ifølge det foregående krav, omfattende fra 0,01 til 0,1 vægt%, fortrinsvis fra 0,025 til 0,075 vægt% capsaicin.
7. Sammensætning ifølge et hvilket som helst af de foregående krav, ligeledes omfattende en fødevareingrediens.
8. Sammensætning ifølge det foregående krav, hvor fødevareingrediensen er udvalgt blandt piperin eller et zinkderivat.
9. Sammensætning ifølge krav 7 eller 8, omfattende fra 0,01 til 4 vægt%, fortrinsvis fra 0,1 til 1 vægt% piperin.
10. Sammensætning ifølge krav 7 eller 8, omfattende fra 0,01 til 2 vægt%, fortrinsvis fra 0,1 til 1,5 vægt% zinkderivat.
11. Kosttilskud, omfattende en sammensætning ifølge et hvilket som helst af krav 1 til 10.
12. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, i form af en topisk sammensætning.
13. Sammensætning ifølge krav 12, til anvendelse i behandlingen eller forebyggelsen af akutte eller kroniske betændelsessygdomme, især til behandlingen eller forebyggelsen af leddegigt.
14. Sammensætning ifølge et hvilket som helst af krav 1 til 6, der er beregnet til anvendelse som medikament.
15. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, til anvendelse i behandlingen eller forebyggelsen af akutte eller kroniske betændelsessygdomme, især til behandlingen eller forebyggelsen af leddegigt.
16. Kit, omfattende - en første sammensætning ifølge et hvilket som helst af kravene 1 til 6, - en anden sammensætning, omfattende et antiinflammatorisk middel.
17. Fremgangsmåde til fremstilling af en sammensætning ifølge kravene 2 til 10, omfattende (i) fremstilling af et ekstrakt af vindrueskal, der opnås med udvælgelsen af mindst én rød vindruekvas og koncentration af de polyphenoliske fraktioner af kvasen, (ii) blanding af ekstrakten fra (i) og et Propolis-ekstrakt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1157995A FR2979826B1 (fr) | 2011-09-08 | 2011-09-08 | Composition anti-inflammatoire |
PCT/EP2012/067584 WO2013034746A1 (fr) | 2011-09-08 | 2012-09-07 | Compositions anti - inflammatoires comprenant de la malvidine - 3 - o - beta glucoside et un extrait de propolis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2800574T3 true DK2800574T3 (da) | 2017-09-25 |
Family
ID=46829763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12756729.5T DK2800574T3 (da) | 2011-09-08 | 2012-09-07 | Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt |
Country Status (10)
Country | Link |
---|---|
US (1) | US9308231B2 (da) |
EP (1) | EP2800574B1 (da) |
JP (1) | JP6043795B2 (da) |
BR (1) | BR112014005413B8 (da) |
CA (1) | CA2848009C (da) |
DK (1) | DK2800574T3 (da) |
ES (1) | ES2646444T3 (da) |
FR (1) | FR2979826B1 (da) |
PL (1) | PL2800574T3 (da) |
WO (1) | WO2013034746A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6708376B2 (ja) * | 2015-07-10 | 2020-06-10 | 株式会社山田養蜂場本社 | IFN−γ及び/又はIL−17の産生抑制剤、並びにTh1細胞及び/又はTh17細胞の分化抑制剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2946452B2 (ja) * | 1994-11-04 | 1999-09-06 | カディラ ラボラトリーズ リミテッド | ピペリンを含む組成物 |
JP2003192603A (ja) * | 2001-12-27 | 2003-07-09 | National Institute Of Advanced Industrial & Technology | 抗ガン剤および健康食品 |
JP2003238422A (ja) * | 2002-02-12 | 2003-08-27 | Toyo Shinyaku:Kk | アポトーシス誘導剤および健康食品 |
KR20050008453A (ko) * | 2002-03-08 | 2005-01-21 | 바쿠레시 마파탈 카마르 | 결핵 관리에 유용한 약제학적 조성물의 제조방법 |
JP2006514962A (ja) * | 2003-01-30 | 2006-05-18 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | キャラウェー抽出物及びその分画の活性を強化する生物学的利用能 |
JP2005001998A (ja) * | 2003-06-09 | 2005-01-06 | Api Co Ltd | 血圧降下剤及びその製造方法、並びにプロポリス組成物及び食品製剤 |
UA90668C2 (ru) * | 2004-02-19 | 2010-05-25 | Бёрингер Ингельхайм Интернациональ Гмбх | Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство |
CN1994357A (zh) * | 2005-12-31 | 2007-07-11 | 王凯 | 蓝莓与蜂胶配伍的提高免疫力的组合物 |
FR2916141B1 (fr) * | 2007-05-15 | 2009-11-13 | Univ Victor Segalen Bordeaux 2 | Activite anti-polyarthrite rhumatoide de la malvidine -3-o-beta-glucoside in vivo. |
FR2949197B1 (fr) | 2009-08-21 | 2012-08-03 | Loic Renard | Composition alimentaire antibacterienne |
-
2011
- 2011-09-08 FR FR1157995A patent/FR2979826B1/fr not_active Expired - Fee Related
-
2012
- 2012-09-07 CA CA2848009A patent/CA2848009C/fr active Active
- 2012-09-07 WO PCT/EP2012/067584 patent/WO2013034746A1/fr active Application Filing
- 2012-09-07 ES ES12756729.5T patent/ES2646444T3/es active Active
- 2012-09-07 DK DK12756729.5T patent/DK2800574T3/da active
- 2012-09-07 BR BR112014005413A patent/BR112014005413B8/pt active Search and Examination
- 2012-09-07 JP JP2014529007A patent/JP6043795B2/ja active Active
- 2012-09-07 US US14/343,449 patent/US9308231B2/en active Active
- 2012-09-07 EP EP12756729.5A patent/EP2800574B1/fr active Active
- 2012-09-07 PL PL12756729T patent/PL2800574T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014005413B1 (pt) | 2021-08-03 |
US9308231B2 (en) | 2016-04-12 |
JP6043795B2 (ja) | 2016-12-14 |
PL2800574T3 (pl) | 2018-01-31 |
US20140314888A1 (en) | 2014-10-23 |
CA2848009C (fr) | 2020-12-29 |
FR2979826B1 (fr) | 2013-12-27 |
JP2014526451A (ja) | 2014-10-06 |
CA2848009A1 (fr) | 2013-03-14 |
BR112014005413B8 (pt) | 2021-12-14 |
FR2979826A1 (fr) | 2013-03-15 |
BR112014005413A2 (pt) | 2017-04-04 |
WO2013034746A1 (fr) | 2013-03-14 |
EP2800574B1 (fr) | 2017-08-09 |
ES2646444T3 (es) | 2017-12-13 |
EP2800574A1 (fr) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Makchuchit et al. | The anti-allergic and anti-inflammatory effects of Benjakul extract (a Thai traditional medicine), its constituent plants and its some pure constituents using in vitro experiments | |
Vetal et al. | Anti-inflammatory and anti-arthritic activity of type-A procyanidine polyphenols from bark of Cinnamomum zeylanicum in rats | |
Pallarès et al. | Grape seed procyanidin extract reduces the endotoxic effects induced by lipopolysaccharide in rats | |
Bao et al. | Genkwanin ameliorates adjuvant-induced arthritis in rats through inhibiting JAK/STAT and NF-κB signaling pathways | |
Tag et al. | Potential anti-inflammatory effect of lemon and hot pepper extracts on adjuvant-induced arthritis in mice | |
JP5331962B2 (ja) | 炎症性疾患のための薬草組成物 | |
Tamashiro Filho et al. | Evaluation of antiulcer activity and mechanism of action of methanol stem bark extract of Lafoensia pacari A. St.-Hil.(Lytraceae) in experimental animals | |
Martin et al. | Aronia berry (Aronia mitschurinii ‘Viking’) inhibits colitis in mice and inhibits T cell tumour necrosis factor-α secretion | |
Liu et al. | Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra | |
Zarei et al. | Systematic review of anti-rheumatic medicinal plants: An overview of the effectiveness of articular tissues and joint pain associated with rheumatoid arthritis | |
Yang et al. | Nobiletin mitigates NAFLD via lipophagy and inflammation | |
EA023717B1 (ru) | Применение композиции для понижающей регуляции/ингибирования pge2 | |
Nisar et al. | Modulation of T-helper cytokines and inflammatory mediators by Atropa accuminata. Royle in adjuvant induced arthritic tissues | |
DK2800574T3 (da) | Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt | |
Rai et al. | Anti–oxidation actions of curcumin in two forms of bed rest: oxidative stress serum and salivary markers | |
Jainu et al. | Protective role of ascorbic acid isolated from Cissus quadrangularis on NSAID induced toxicity through immunomodulating response and growth factors expression | |
ES2426174T3 (es) | Composición herbácea para trastornos inflamatorios | |
Uahomo et al. | Antidiarrheal Properties of Aqueous leaf extract of Cyathula prostrata on Castor oil-induced Diarrhoea in Wistar Rats | |
Lee et al. | Anti-arthritis effect of mangostins from G. Mangostana | |
Zhou et al. | Effects of fluoride on expression of cytokines in the hippocampus of adult rats | |
KR101179966B1 (ko) | 항염증 효과를 갖는 관절염 치료를 위한 약제학적 조성물 | |
Bilal et al. | Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model. | |
Tiwari et al. | Evaluation of antiulcer and antianxiety activity of Aphanmixis polystachya stem bark extract on rats | |
KR101332824B1 (ko) | 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
Abdelhafez et al. | Hypolipidemic Effects of Aphanizomenon flos-aquae and Slimquick on Cardiac Muscle Fibers of the Adult Male Albino Rats |